

Mouse Anti-VEGFC (Flt4L) [E6]: MC0062, MC0062RTU7

Intended Use: For Research Use Only

Description: The onset of angiogenesis is believed to be an early event in tumorigenesis and may facilitate tumor progression and metastasis. Several growth factors with angiogenic activity have been described. These include fibroblast growth factor (FGF), platelet derived growth factor (PDGF) and vascular endothelial growth factor (VEGF). VEGF is a dimeric glycoprotein with structural homology to PDGF. Several variants of VEGF have been described that arise by alternative mRNA splicing. It has been speculated that VEGF may function as a tumor angiogenesis factor in vivo. Two additional proteins, designated VEGFB and VEGF-C, share a significant degree of homology with VEGF. VEGFB is abundantly expressed in heart and skeletal muscle and is frequently coexpressed with VEGF. VEGFC binds to and specifically activates VEGFR3 and VEGFR2. Growth factor active in angiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults.


Specifications

Clone: E6
 Source: Mouse
 Isotype: IgG2a/k
 Reactivity: Human, mouse, rat
 Immunogen: Human VEGFC N-terminus epitope aa 103-137
 Localization: Secreted
 Formulation: Antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN₃)
 Storage: Store at 2°- 8°C
 Applications: IHC, IF, IP, WB
 Package:

Description	Catalog No.	Size
VEGFC (Flt4L) Concentrated	MC0062	1 ml
VEGFC (Flt4L) Prediluted	MC0062RTU7	7 ml

IHC Procedure

Positive Control Tissue: Small Intestine
 Concentrated Dilution: 50-200
 Pretreatment: Citrate pH6.0 or EDTA pH8.0, 15 min Pressure Cooker or 30-60 min water bath at 95°-99°C
 Incubation Time and Temp: 30-60 minutes @ RT
 Detection: Refer to the detection system manual
 * Result should be confirmed by an established diagnostic procedure.



FFPE human lymph node stained with anti-VEGFC using DAB

References:

1. Foxp3 is correlated with VEGF-C expression and lymphangiogenesis in cervical cancer. Tang J et al. W J Surg Oncol. 2017.
2. Prognostic significance of VEGF-C immunohistochemical expression in colorectal cancer: A meta-analysis. Zong S et al. Clin Chim Acta. 2016.
3. The sinus venosus contributes to coronary vasculature through VEGFC-stimulated angiogenesis. Chen HI et al. Development. 2014.

Doc. 100-MC0062
Rev. A